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ABSTRACT
The tumour suppressor protein ARF provides a
defence mechanism against hyperproliferative
stresses that can result from the aberrant activation
of oncogenes. Accordingly, ARF is silenced or
deleted in many human cancers. Activation of ARF
can arrest growth and cell cycle progression, or
trigger apoptosis. A principle mediator of these
effects is p53, which ARF stabilizes by binding and
inhibiting MDM2. However, ARF has additional
targets and remains able to block growth in the
absence of p53, albeit less efficiently. For example,
ARF can suppress rRNA production in a p53-
independent manner. We have found that the
synthesis of tRNA by RNA polymerase III is also
inhibited in response to ARF. However, in contrast
to its effects on rRNA synthesis, ARF is unable to
inhibit tRNA gene transcription when p53 is ablated.
These results add to the growing list of cellular
changes that can be triggered by ARF induction.
INTRODUCTION
The tumour suppressor ARF is a small nucleolar protein,
much of which is encoded by an alternative reading frame
within exon 2 of the INK4a locus (1). It is induced by
abnormal hyperproliferative stimuli and serves to provide
protection against oncogenic stress (2–4). For example,
ARF induction can be triggered by deregulation of
cellular oncogenes, such as E2F-1, Myc and Ras (5–8).
It has been described as a circuit breaker, which monitors
the strength of mitogenic signals and allows growth and
proliferation under normal circumstances, but not when
cells receive inappropriate oncogenic stimuli (2–4). Loss of
ARF expression, as occurs in many malignancies, can
abrogate this surveillance mechanism and increase cancer
susceptibility. Accordingly, mice lacking ARF are highly
prone to tumour development (9). For example, Em-Myc
transgenic mice develop much more rapid and aggressive
lympholeukaemias if they lack both ARF alleles (10).
Conversely, increased gene dosage of the Ink4a/ARF
locus confers cancer resistance to transgenic mice (11).
A key way in which ARF protects against oncogenic
stress is by raising p53 levels, which can lead to cell cycle
arrest or apoptosis (2,4,12). ARF does this by binding to
MDM2, a ubiquitin ligase that catalyses p53 degradation;
this interaction sequesters MDM2 and also blocks its
ligase activity, thereby stabilizing p53 (13,14). Recent data
suggest that tumour suppression by p53 may hinge upon
its ARF-dependent ability to respond to oncogenic stress
(15,16). In addition, ARF can inhibit cell growth and
proliferation in the absence of functional p53, albeit less
eﬃciently (2,17,18). Thus, overexpressing ARF can
prevent proliferation of p53-negative mouse embryonic
ﬁbroblasts (MEFs), although their arrest is slower than
that of wild-type controls (17). Furthermore, mice
engineered to lack both p53 and ARF develop cancers
at a faster rate than animals lacking only one of these
tumour suppressors, clear genetic evidence that ARF has
p53-independent functions in vivo (18). Apart from
MDM2, a variety of proteins have been reported to
interact with ARF (4,19). Furthermore, there is strong
evidence that ARF can inﬂuence ribosome biogenesis in a
p53-indpendent manner (20,21). This may be of funda-
mental importance in ensuring that growth (accumulation
of mass) is inhibited in parallel with cell cycle arrest.
ARF was found to reduce production of 5.8S, 18S and
28S rRNAs by inhibiting the processing of pre-rRNA
precursors in a manner independent of p53 and MDM2
(21,22). This activity maps to a region of ARF that is
especially well conserved through evolution and is
required for it to suppress proliferation (21). Several
proteins involved in ribosome biogenesis interact with
ARF (20,22). One of these is nucleophosmin (B23), a
nucleolar endoribonuclease that is required for rRNA
processing and cell cycle progression (20,22,23). ARF can
interfere with the function of nucleophosmin and
inhibit rRNA maturation (20,22,23). ARF has also been
reported to inhibit transcription of rRNA genes by RNA
polymerase (pol) I (24). Since cell growth and
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ability of ARF to disrupt this process may contribute to
its role as a tumour suppressor, even in the absence of p53.
Indeed, it has been suggested that the primordial role of
ARF was to slow ribosome biogenesis in response to
hyperproliferative stresses caused by oncogene activation;
its subsequent linkage to p53 via MDM2 may have
evolved to provide a more eﬃcient checkpoint for
coupling ribosome production with p53-dependent inhib-
itors of the cell cycle (19,21).
In most situations, the production of large rRNAs by
pol I is regulated co-ordinately with the production of 5S
rRNA and tRNA by pol III (27,28). This is an economical
arrangement, since the four rRNAs are required in
equimolar amounts within the ribosome and the demand
for tRNA must reﬂect the availability of ribosomes.
Although pols I and III use very diﬀerent sets of
transcription factors, they are both targeted directly by
several key growth regulators, including c-Myc, Erk, RB
and p53 (28). For example, both the pol I-speciﬁc factor
SL1 and the pol III-speciﬁc factor TFIIIB are bound and
inactivated by p53 (29–32). ARF can therefore block
rRNA accumulation by allowing p53 to inactivate SL1, as
well as inhibiting pol I transcription and the processing of
pre-rRNA independently of p53 (20,21,24,31). Precedent
would suggest that a similar scenario may control the
production of pol III products. This study conﬁrms that
pol III transcription is indeed inhibited in response to
ARF. However, in contrast to the pol I system, we ﬁnd no
evidence for a p53-independent eﬀect of ARF in this case.
MATERIALS AND METHODS
Cell linesand culture
F9 cells were cultured at 378C in DMEM supplemented
with 10% FCS. NARF2 cells, derived from the human
osteosarcoma cell line U2OS and containing a stably
integrated p14
ARF gene under the control of IPTG (33),
were cultured at 378C in DMEM supplemented with 10%
FCS, G418at a concentration of 300mg/ml and hygro-
mycin at 150mg/ml. E6-expressing NARF2 cells were
cultured in the same way but with puromycin at a
concentration of 1.5mg/ml. Expression of p14
ARF was
induced by the addition of IPTG at a concentration of
1mM.
Transient transfections
F9 cells were transiently transfected with pcDNA3HA-
E2F1, an expression vector encoding full-length human
E2F1, or pcDNA3 as a control. Transfection into F9 cells
was achieved using superfect (Qiagen, Valencia, CA,
USA) and cells were cultured for 24h before harvesting.
NARF2 cells were transfected with pSUPER-p53 or
empty pSUPER control (34) using the Nucleofector
system (Amaxa Biosystems, Gaithersburg, MD, USA),
according to the manufacturer’s instructions for U2OS
cells. Cells were harvested after 48h and RNA was
extracted using TRI reagent (Sigma, St. Louis, MO,
USA), according to the manufacturer’s instructions.
Gene expression assays
Primer extension reactions were carried out as previously
(35) using VA1-speciﬁc (50-CACGCGGGCGGTAACCG
CATG-30) and GFP-speciﬁc (50-CGTCGCCGTCCAGC
TCGACCAG-30) labelled primers.
RT-PCR analysis was performed as described pre-
viously (36). For p21 mRNA, primers were 50-CACCTC
CTCATGTACATACC-30 and 50-CAGGTCTGAGTGT
CCAGGAA-30 and the cycling parameters were: 958C for
2min, then 25 cycles of 958C for 1min, 588C for 30s and
728C for 1min, followed by 728C for 3min.
Antibodies and western blotting
Whole cell extracts were prepared as previously by a
freeze–thaw protocol (37) and protein concentration
determined by the Bradford assay. Western immunoblot
analysis was performed as previously described (37) using
anti-p53 antibodies DO-1 (Pharmingen, San Diego, CA,
USA) and 1C12 (Cell Signaling Technology, Beverley,
MA, USA), anti-p19 ARF antibody ab80 (Abcam,
Cambridge, UK), anti-p14 ARF antibodies FL-132 and
C-18, anti-p21 antibody C19, anti-E2F1 antibody KH95,
anti-actin antibody C11 (all Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and anti-Brf1 antibody 330 (38).
RESULTS
Oncogenic stress caused by ectopicE2F1 overexpression
results inrepression ofpol IIItranscription
E2F1 has been shown to induce expression of ARF and
thereby stabilize p53 (7,8,39). To test whether pol III
transcription is regulated under these conditions, F9 cells
were transfected with a plasmid encoding human E2F1,
along with the VA1 gene as a pol III reporter and GFP as
an internal control. Cells were harvested after 24h and
production of RNA from both VA1 and GFP reporters
was assessed by quantitative primer extension. Western
immunoblotting demonstrated that exogenous expression
of E2F1 resulted in the induction of ARF and stabiliza-
tion of p53 (Figure 1A). It also caused dramatic inhibition
of the VA1 pol III reporter, whereas little or no eﬀect was
observed on pol II-dependent expression of the GFP
control (Figure 1B). These data demonstrate that an
oncogenic stress which induces ARF can trigger repres-
sion of a pol III reporter.
Inductionof ARFresults inrepression ofpolIIItranscription
To test directly if pol III transcription responds to ARF,
we used the NARF2 cell line, a derivative of U2OS
osteosarcoma cells carrying an IPTG-inducible ARF gene
(33). Immunoblotting revealed a substantial increase in
expression of ARF after 24h of IPTG treatment
(Figure 2A). As expected, this was accompanied by an
elevated level of p53, reﬂecting its stabilization by ARF
(33). Functional activation of p53 was suggested by the
induction of p21, a well-characterized p53 target
(Figure 2A). This was supported by cell cycle analysis,
which showed G1 arrest when ARF was induced (data not
shown).
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cells revealed a marked decrease in tRNA expression
following ARF induction (Figure 2B). These assays used
intron-speciﬁc primers to detect primary tRNA transcripts
and are considered to provide a measure of ongoing pol
III transcription, because the primary products are
processed very rapidly into mature tRNA (36).
However, the possibility that ARF could aﬀect tRNA
processing has not been excluded. The observed eﬀect of
ARF induction on levels of pre-tRNA was speciﬁc, since
expression of a pol II-dependent control transcript
encoding acidic ribosomal phosphoprotein P0 (ARPP
P0) remained undiminished. Because treatment of par-
ental U2OS cells with IPTG did not inﬂuence pre-tRNA
expression (Figure 2C), we believe that the response seen
in NARF2 cells reﬂects the presence of the IPTG-
inducible ARF gene.
A time course was conducted to compare the repression
of pol III output with the induction of ARF and p53.
Immunoblotting conﬁrmed that ARF levels become
elevated within 9h of IPTG addition and remain high at
all subsequent time points (Figure 3A). Induction of p53
was detected at the earliest time points, before maximal
levels were reached by 9h. One can infer from the p53
response that ARF is also induced at the earlier time
points, but ARF is less readily detected than p53 due to
inferior antibodies. The data suggest that induction of
ARF stabilizes p53, as predicted. Analysis of tRNA
expression revealed clear repression 3h after IPTG
addition, which was coincident with the accumulation of
p53in these cells (Figure 3B). Expression of the p53-
responsive p21 gene increased following ARF induction,
consistent with the stabilization of p53. However, activa-
tion of p21 was less dramatic than the pol III response and
also slower to appear, only becoming evident at the 6-h
time point. Thus, ARF can trigger a pol III response,
which is faster and stronger than the well-documented
induction of a paradigm p53 target gene. The rapidity with
which pol III transcription is repressed indicates that
regulation is likely to be direct, whereas an indirect
response to cell cycle changes would follow p21 induction.
RepressionofpolIIItranscriptionbyARFisdependentonp53
We used RNAi to test if the repression of tRNA gene
expression in response to ARF is dependent on p53.
NARF2 cells were transfected with pSUPER-p53, which
encodes an shRNA against p53, or the empty pSUPER
vector as control (34). Western blotting conﬁrmed that
p53 levels were reduced speciﬁcally by the p53 shRNA,
and that this remained the case following ARF induction
with IPTG (Figure 4A). This partial knock-down of p53
caused a substantial elevation in tRNA expression,
consistent with the role of p53in restraining pol III
transcription (Figure 4B). Furthermore, it prevented the
repression of tRNA expression that otherwise accompa-
nies ARF induction in these cells. Thus, the level of tRNA
is no longer diminished in response to ARF when p53 has
been depleted (compare lanes 2 and 4).
AB
IPTG + − IPTG −
−
+
ARF
p53
p21
actin
tRNA
ARPP P0
mRNA
C
IPTG +
tRNA
ARPP P0 
mRNA
Figure 2. Induction of ARF in NARF2 cells leads to stabilization of
p53 and repression of pol III transcription. (A) NARF2 cells were
treated with IPTG (1mM) to induce ARF expression 24h prior to
harvesting. Western blot of extracted protein using anti-p14
ARF
antibody FL-132, anti-p53 antibody DO-1, anti-p21 antibody C19
and anti-actin antibody C11, as indicated. (B) RT-PCR analysis was
performed on cDNAs generated by reverse transcription of total
extracted RNA using primers speciﬁc for tRNA and ARPP P0 mRNA,
as indicated. (C) Parental U2OS cells were treated with 1mM IPTG for
24h prior to harvesting and RT-PCR analysis was performed using
primers speciﬁc for tRNA and ARPP P0 mRNA, as indicated.
AB
Control E2F1 Control E2F1
E2F1
ARF
p53
actin
VA1 
GF 
Figure 1. Overexpression of E2F1 can induce ARF and p53 and inhibit
pol III transcription. F9 cells were co-transfected in duplicate with
pVA1 (1mg), pGST (1mg) and 15mg of empty vector (control) or vector
encoding full-length E2F1, as indicated. RNA and protein were isolated
48h after transfection. (A) Western blot of exogenous E2F1 using anti-
E2F1 (human) antibody KH95 and of endogenous p19
ARF using anti-
p19
ARF antibody ab80, p53 using anti-p53 antibody 1C12 and actin, to
conﬁrm equal loading of protein, using anti-actin antibody C11. (B)
Primer extension analysis of extracted RNA using primers speciﬁc for
VA1 (upper panel), and GFP (lower panel).
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produces the E6 product of HPV16, an oncoprotein,
which targets p53 for degradation (33). When ARF is
induced in E6 NARF2 cells, p53 levels do not increase
(Figure 5A) and tRNA expression is not repressed
(Figure 5B). These data support the inference from
RNAi (Figure 4) that ARF-mediated repression of pol
III transcription requires induction of p53.
DISCUSSION
This study establishes that pol III transcription is
repressed in response to oncogenic stress caused by
overexpression of E2F1. The ARF gene promoter is
bound and activated by E2F1 (7,39) and we have shown
directly that induction of ARF can trigger a potent
repression of pol III transcription. This response is lost if
p53 is neutralized using RNAi or the E6 viral oncoprotein.
The data suggest that the ARF/p53 pathway can suppress
pol III activity as part of the protective response to
hyperproliferative stresses induced by aberrant oncogene
activation. This may help limit the growth capacity of
cells.
Even in the absence of p53, ARF is able to inhibit
production of mature rRNA, an eﬀect, which will
undoubtedly have a major impact on ribosome accumula-
tion and hence cell growth and proliferation (20,21,24).
Since pol III output is frequently coordinated with the
production of large rRNA (27,28), we wondered if ARF
A
p53 RNAi
p53 RNAi
−+−+
IPTG −−++
−+−+
−−++
p53
ARF
Actin
B
IPTG 
tRNA
ARPP P0 
mRNA
Figure 4. ARF-mediated repression of pol III-transcript expression is
blocked by RNAi of p53. NARF2 cells were transfected with empty
vector (lanes 1 and 3) or vector encoding p53-speciﬁc shRNA (lanes 2
and 4). IPTG was added 24h later (lanes 3 and 4) and cells were
harvested after a further 24h. (A) Western blot of extracted protein
using anti-p53 antibody DO-1 (upper panel), anti-p14 antibody FL-132
(middle panel) and anti-actin antibody C11 (lower panel). (B) RT-PCR
analysis performed on cDNAs prepared from total extracted RNA
using primers speciﬁc for tRNA (top panel), and ARPP P0 mRNA
(bottom panel).
A Hours after induction
Hours after induction
04 8
ARF
p53
Actin
B
tRNA
p21 mRNA
ARPP P0 mRNA 
24 16 12 9 6 3
04 8 24 16 12 9 6 3
Figure 3. Time course of ARF induction and downstream events.
NARF2 cells were treated with IPTG (1mM) and RNA and protein
harvested at the time points indicated. (A) Western blot using anti-p14
antibody FL-132 (upper panel), anti-p53 antibody DO-1 (middle panel)
and anti-actin antibody C11 (lower panel). (B) RT-PCR analysis using
primers speciﬁc for tRNA (upper panel), p21 mRNA (middle panel)
and ARPP P0 mRNA (bottom panel).
Nucleic Acids Research, 2007, Vol. 35, No. 9 3049might also have a direct eﬀect on the pol III system.
However, our data argue that this is not the case and that
the impact of ARF on pol III transcription is mediated
through p53, at least in U2OS cells. This conclusion is
consistent with the fact that p53-knockout ﬁbroblasts
display highly elevated levels of ARF (40) and yet also
transcribe tRNA and 5S rRNA genes much more actively
than matched wild-type cells (30). Although the possibility
remains of a more direct eﬀect under other circumstances,
the available evidence indicates that ARF needs p53in
order to restrain pol III transcription.
The abundance and activity of p53 can be raised by a
variety of diﬀerent stresses, including exposure to DNA-
damaging agents, hypoxia, ribonucleotide depletion and
inappropriate growth signals resulting from aberrant
oncogene activation (41–46). Under unstressed conditions,
the level of p53 is kept low by proteolytic degradation, but
stress causes p53 to accumulate rapidly, primarily due to
its stabilization (41–46). It also triggers a complex series of
modiﬁcations, which can determine the ability of p53 to
bind and regulate its many targets (41–46). The nature of
the response pathways and the resultant modiﬁcations can
vary dramatically between diﬀerent cell types and distinct
kinds of stress (45,46). A good example is provided by
serine 15 of p53, which is phosphorylated in response to
DNA damage, but not in response to oncogenic stress
(47). Because of these variations in the mode of activation,
the sets of genes controlled by p53 depend upon the
particular stress conditions. For example, DNA damage
causes p53 to induce the p21 gene, but the same gene
shows little or no response to p53 activation under
hypoxic conditions (48). Although previous studies had
established that pol III transcription can respond strongly
to p53 in vitro or in vivo, they did not determine the
physiological circumstances under which this control
becomes most apparent. Indeed, artiﬁcial induction of
p53in TR9-7 cells from a tetracycline-dependent promoter
had minimal eﬀect on pol III activity (49). Furthermore,
UV treatment of MCF-7 cells was found to induce
endogenous p53, but again caused little or no repression
of pol III transcription (50). UV-induced acetylation of
p53in its C-terminal domain encouraged its binding to the
p21 gene but excluded it from pol III-transcribed genes,
when tested in parallel (50). This striking result empha-
sizes the complexity of the p53 response and how it can
vary between diﬀerent genes and stimuli. A more robust
eﬀect on pol III transcription may occur in other cell types
or with other types of DNA damage. Alternatively, the
repression of pol III may not be a signiﬁcant part of the
protective repertoire of p53 under these conditions. Our
data suggest that the ability of p53 to control pol III
transcription is instead more important when a cell
induces ARF. Indeed, under these circumstances we ﬁnd
a robust pol III response that is faster and more potent
than the induction of p21, a paradigm direct target of p53.
Repression of pol III transcription may therefore form
part of the protective response to hyperproliferative
signals triggered by aberrant oncogene activation. It is
noteworthy that recent evidence suggests that the tumour
suppression function of p53 may be mediated primarily by
its ability to protect against oncogenic stress, whereas its
responsiveness to DNA damage may be much less
important (15,16).
It has been reported that p53 induction in TR9-7 cells
causes selective degradation of the TFIIIB subunit Brf1
(49). We looked for a similar eﬀect in NARF2 cells, but
found no change in Brf1 levels following induction of
ARF and the consequent stabilization of p53 (Figure 5A).
Brf1 levels were also unchanged in response to p53
induction in H1299 cells (32). We therefore do not believe
that destabilization of Brf1 is a general feature of the pol
III response to p53.
In addition to E2F1, other proto-oncogenes including
Ras and c-Myc can induce ARF expression and might
therefore be expected to down-regulate pol III output (5).
This seems contrary to the published evidence that Ras
and c-Myc can stimulate pol III transcription robustly in a
variety of cell lines (51,52). There is also evidence that
ARF can directly antagonize the ability of c-Myc to
activate a subset of its transcriptional targets (19,40,53)
An explanation is suggested by the fact that most cell lines
A NARF2
IPTG   −− +
−+−+
E6 NARF2
IPTG +
ARF
p53
Brf1
tRNA
Actin
ARF
p53
Brf1
Actin 
B
ARPP P0 mRNA
NARF2     E6 NARF2
IPTG
Figure 5. ARF-mediated repression of pol III-transcript expression is
blocked by HPV16 E6. Matched NARF2 and E6 NARF2 cells were
cultured for 24h with or without IPTG, as indicated. (A) Western blot
analysis using anti-ARF antibody FL-132, anti-p53 antibody DO-1,
anti-Brf1 antibody 330 and anti-actin antibody C11, as indicated. (B)
RT-PCR analysis using primers speciﬁc for tRNA and ARPP P0
mRNA, as indicated.
3050 Nucleic Acids Research, 2007, Vol. 35, No. 9are compromised in the function of ARF and/or p53 and
have therefore lost their protection against pol III
activation by c-Myc or Ras (33). For example, the
U2OS cells used in this study are ARF-negative, providing
a null background to study the eﬀects of artiﬁcial ARF
induction (33). Indeed, loss of either ARF or p53 is
essential for cell immortalization by c-Myc (5,10). When
intact, the ARF-p53 pathway provides a protective
safeguard against deregulated oncogenes, inhibiting a
variety of processes that impact on growth and cell cycle
progression, including pol III transcription. When either
ARF or p53are lost during cell immortalization, a
restraint on pol III output is removed and Ras or c-Myc
become free to activate the system fully.
Inappropriate hyperproliferative signals cause ARF to
initiate mechanisms that inhibit both cell cycle progression
and the accumulation of mass (i.e. growth). Coordination
of these processes is necessary to maintain cell size. ARF’s
ability to restrain the production of rRNA and hence
ribosomes provides a potent means of growth control.
This pathway is bolstered by its ability to trigger p53-
dependent repression of pol III transcription. Such an
arrangement has clear beneﬁts in terms of metabolic
economy, as it will prevent the production of excess tRNA
and 5S rRNA that is surplus to requirements when
ribosome production is limited. ARF may be added to the
growing list of oncogenes and tumour suppressors that,
either directly or indirectly, can impinge upon the pol III-
transcription machinery.
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